Avalara Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Avalara, Inc. (NYSE: AVLR) today announced the closing of its initial public offering of 8,625,000 shares of common stock, including the full exercise by the underwriters of their option to purchase 1,125,000 additional shares of common stock, at a price to the public of $24.00 per share. The shares began trading on the New York Stock Exchange on June 15, 2018 under the symbol “AVLR.”
Goldman Sachs & Co. LLC, J.P. Morgan, and BofA Merrill Lynch acted as book-running managers for the offering. JMP Securities, KeyBanc Capital Markets, and Stifel acted as co-managers.
The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at 866-471-2526, or by email at firstname.lastname@example.org, or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or email at email@example.com. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
New Guidance From ADA and EASD Recommends Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Patients with Type 2 Diabetes16.10.2018 13:15 | Pressemelding
As the European distributor of INVOKANA ® (canagliflozin) and VOKANAMET ® (canagliflozin and metformin) Mundipharma welcomes the news that SGLT2i’s, including canagliflozin, have now been included as an important treatment option in the newly published 2018 ADA/EASD Consensus Report in the early management of T2DM patients with established ASCVD, HF, CKD and also in patients without cardiovascular disease (CVD) especially where there is a compelling need to minimize weight gain or promote weight loss or a need to minimize the risk of hypoglycaemia. The new guidance was co-published in Diabetologia, the journal of EASD, and Diabetes Care, the journal of the ADA, during the annual meeting of EASD in Berlin, Germany on October 5.1 Updates to the guidance took into consideration recent evidence from large CV outcome trials (CVOTs), which included the CANVAS programme, the largest completed and published CV outcomes trial to date for an SGLT2i, which has shown that canagliflozin reduces the
Brightree Launches First Patient App for HME16.10.2018 13:05 | Pressemelding
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patient Hub to personalize the patient experience and increase revenue for home medical equipment (HME) providers. Patient Hub is a patient engagement app that automates and simplifies how HME providers connect with their patients. It eliminates the need for multiple web portals and consolidates all patient interactions into one secure platform. By improving ease of engagement and automation, Patient Hub empowers care, frees up resources and creates opportunities to accelerate cash flow. The Patient Hub app allows providers to automate simple, repetitive processes such as sending out appointment reminders and requests for insurance updates, or delivering order status and tracking updates. Patients can initiate and complete tasks as well, including updating account information, reordering suppli
KYMCO Announces Entry Into India With Ionex16.10.2018 12:40 | Pressemelding
KYMCO announces its official entry into India with its game-changing Ionex electric scooter total solution. In partnership with Twenty Two Motors, an Indian company that focuses on developing advanced connected electric vehicles, KYMCO is set to revolutionize the two-wheeler sector in India by bringing the new era of electric scooters and building the open energy platforms long awaited by Indian customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005636/en/ Allen Ko, Chairman, KYMCO (Photo: Business Wire) India is the largest two-wheeler market in the world. The Indian government is actively promoting green movement through policies that encourage the use of electric vehicles as well as the establishment of EV infrastructure. The latest ‘National E-Mobility Programme’ aims to shift one third of petrol and diesel vehicles to electric by 2030. The government has a strong motivation for “go electric, go green” revol
AGCO Chairman, President and Chief Executive Officer Martin Richenhagen Receives the French Government's Prestigious Legion of Honor16.10.2018 12:00 | Pressemelding
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announces that Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO Corporation, has been named a Chevalier (Knight) of the Légion d'Honneur (Legion of Honor) by the government of France. This high-ranking honorary decoration was bestowed during a recent ceremony held at AGCO’s global headquarters in Duluth, in the presence of the French Consul General in Atlanta, Louis de Corail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005270/en/ Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO Corporation, has been named a Chevalier (Knight) of the Légion d'Honneur (Legion of Honor) by the government of France during a recent ceremony in Duluth, Georgia, USA. (Photo: Business Wire) The Legion of Honor, established by Napoléon Bonaparte in 1802, is the hi
Fujitsu to Demonstrate New “Super-Slim” Washable RFID Linen Tags at the EXPOdetergo 18th International Exhibition in Milan, Italy16.10.2018 12:00 | Pressemelding
Fujitsu Frontech North America Inc., a leader in innovative technology and front-end solutions, has announced today that Fujitsu has developed a new line of washable UHF RFID tags only 7 millimeters wide, 30% smaller than current tags, allowing them to be more easily inserted into the seams of washable items. Fujitsu will debut the new “super-slim” tags, as well as their WT-A533 Linen tags and WT-A533L Fashion tags, at the EXPOdetergo 18th International Exhibition, Hall 1 booth # V10, on October 19-22, 2018, at the Fiera Milano Convention Center, Milan, Italy. The Fujitsu “super-slim” washable RFID Linen tags are targeted for availability in the first quarter of 2019. “Fujitsu has been creating RFID solutions for over 20 years. Our engineering and design teams possess sophisticated engineering, design and antenna optimization intellectual property,” says Michi Sugawara, President and CEO of Fujitsu Frontech North America Inc. “By combining this know-how plus our skills in high-volume,
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.16.10.2018 12:00 | Pressemelding
Quotient Sciences, a leading drug development services organization, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing. The Garnet Valley site will focus on developing small molecule oral drug products, supporting development programs from the preclinical stage through to clinical proof-of-concept. Seamless scale-up to late-phase manufacturing and commercial product supply will continue at Quotient’s nearby Chelsea Parkway facility. “Our new facility was built in response to increasing customer demand for our early-phase formulation development and clinical trial manufacturing services,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “The site was specifically designed to optimize our ability to work with highly potent